Quick Answer
Verrica Pharmaceuticals Inc. reported Revenue (ASC 606) of $7.57 million for fiscal year 2024.
Verrica Pharmaceuticals Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2024 | $7.57M | +47.7% |
| 2023 | $5.12M | -43.3% |
| 2022 | $9.03M | -24.7% |
| 2021 | $12.00M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $12.70M | +145.4% | +269.4% |
| March 31, 2025 | $3.44M | -10.1% | +293.1% |
| September 30, 2024 | -$1.78M | -161.1% | -134.4% |
| June 30, 2024 | $5.18M | +2744.5% | +35.3% |
| March 31, 2024 | $3.83M | +10240.5% | +31.2% |
| September 30, 2023 | $2.92M | -64.9% | +1502.7% |
| June 30, 2023 | $182.0K | -15.0% | +391.9% |
| March 31, 2023 | $37.0K | -91.4% | -99.6% |
- Verrica Pharmaceuticals Inc. showed an increase of +47.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2021–2024 period, Verrica Pharmaceuticals Inc.’s revenue (asc 606) has declined by 37.0% (from $12.00 million to $7.57 million).
- The most recent figure is from Verrica Pharmaceuticals Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 11, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: